Low-Dose Aspirin Prevents Kidney Damage in LPS-Induced Preeclampsia by Inhibiting the WNT5A and NF-κB Signaling Pathways

Abstract

Preeclampsia (PE) is a serious pregnancy-related disease, and patients usually present with a high inflammatory response. Previous studies have suggested that aspirin (ASP) may have a role in alleviating the pathogenesis of preeclampsia. However, whether ASP can improve kidney damage and the mechanism for improving it is currently unclear. Here we optimized a lipopolysaccharide (LPS)-induced PE mouse model to identify the role of ASP in renal protection. We found that ASP treatment ameliorated LPS-induced renal failure and pathological changes, the tubular injury was significantly attenuated by ASP. Administration of ASP decreased the renal expression of pro-inflammatory factors, resulting in reduced kidney inflammation. The number of GALECTIN-3-positive cells was reduced, and the up-regulation of IL-6 and TNF-α was decreased. In addition, ASP also suppressed renal cell apoptosis and oxidative stress. An in vitro study indicated that ASP relieved LPS-induced HK-2 cell damage by inhibiting WNT5A/NF-κB signaling. Collectively, our data suggest that ASP is a useful therapeutic option for PE-related kidney injury.

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021

“…Low-dose aspirin was used for its clearly demonstrated anti-thrombotic action, as it could reduce or dampen platelet aggregation, with the aim of preventing micro- or macro-thrombosis during the initial stage of the disease [ 20 , 21 ]. The use of a gastro-protector was considered to avoid the cumulative dangerous effects of the anti-inflammatory agent and the anti-aggregating drug on the stomach, including stress ulceration and gastrointestinal bleeding [ 22 ].…”

Identification of differentially expressed genes and signaling pathways in gestational diabetes mellitus by integrated bioinformatics analysis

“…Polonikov et al [211], Chida et al [212], Yamada et al [213], Zhang et al [214], Kawarazaki et al [215], Ueda et al [216], Bao et al [217], Leng et al [218], Taghvaei et al [219], Norling et al [220], Brown et al [221], Singh et al [222], Liu et al [223], Nie et al [224], Liu et al [225], Sharma et al [226], Liu et al [227], Jain et al [228], Novoyatleva et al [229], Yu et al [230], Sahoo et al [231], Gamboa et al [232], Zeng et al [233], Zabini et al [234], Olivi et al [235], Liu et al [236], Nabrdalik et al [237], Katayose et al [238], Topchieva et al [239], Onal et al [240], Speirs et al [241], Novelli et al [242], Le Hiress et al [243], Chang et al [244], Deng et al [245], Wang et al [246], Dhande et al [247], Yu et al [248] and Li et al [249] showed that CYP2J2, BMPR1B, ROS1, SCN7A, WNT5A, HSD11B2, CYP24A1, WNK3, PPARGC1A, IGF1, OSR1, TLR3, BMP7, POSTN (periostin), ITGB3, THBS1, FLNA (filamin A), TRPC6, SELP (selectin P), VCL (vinculin), NOTCH2, F2RL3, LRP1, CLU (clusterin), SMAD3, PEAR1, MYH9, TGFB1, PDGFA (platelet derived growth factor subunit A), IL6R, TIMP1, TNFRSF1B, CD47, CD74, VCAN (versican), IRF7, NOTCH1, STIM1, CXCR4 and PDE5A expression can be associated with hypertension progression, but these genes might be novel targets for GDM. ROS1 [250], WNT2 [251], PHLDA2 [252], WNT5A [253], HSD11B2 [254], CLDN1 [255], CYP24A1 [256], HRG (histidine rich glycoprotein) [257], TLR3 [258], THBS1 [259], TRPC6 [260], SELP (selectin P) [261], CLU (clusterin) [262], CDKN1A [263], ITGB1 [264], HLA-E [265], IL6R [266], TIMP1 [267], SERPINA1 [268], CD74 [269], PANX1 [270], STIM1 [271] and CXCR4 [272] were revealed to be correlated with disease outcome in patients with preeclampsia. Previously reported studies h...…”

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19

“…Low-dose aspirin has been widely used as an antithrombotic agent. Its use in SARS-CoV-2 infection could help reduce or dampen platelet hyper-aggregation, which may be caused by the binding of the virus spike to platelet ACE2 receptors, and it could be used to prevent thrombosis during the early phase of COVID-19 [ 97 , 98 ].…”